Replication of the Heads Up Atopic Dermatitis Trial With Registry Data

RecruitingOBSERVATIONAL

Enrollment

240

Participants

Timeline

Start Date

August 2, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Atopic Dermatitis

Interventions

DRUG

Upadacitinib

30 mg tablet daily

BIOLOGICAL

Dupilumab

300 mg injection every other week

Trial Locations (1)

RECRUITING

Center for Evidence Based Health Care, Dresden

All Listed Sponsors

lead

Technische Universität Dresden

OTHER